Nivolumab-IRDye800
Phase 1
Nivolumab-IRDye800 is one of 49 therapeutic programs targeting Brain Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
67 competitors in Brain Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Aloxi
AAvyxa
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Bicnu
MMelissa K Accordino
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Namenda
FForest Laboratories
Phase 3
Voranigo
SServier
Phase 3
Taxol
TevaPhase 2
Tarlatamab-Dznl
AmgenPhase 2
Balversa
Johnson & JohnsonPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Nivolumab-IRDye800. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- EEben Rosenthal